Mode
Text Size
Log in / Sign up
Phase 2 N=30 Treatment

Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail

Onychomycosis

Enrolled (actual)
30
Serious AEs
6.7%
Results posted
Sep 2019
Primary outcome: Primary: Treatment Related Adverse Events — 22; 8 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
HTS-519 Insert (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Hallux, Inc.
Primary completion
Oct 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Treatment Related Adverse Events
22; 8

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of HTS-519 Inserts in the treatment of mild to moderate toenail fungus disease of the big toenail.

Eligibility Criteria

Inclusion Criteria

  • Male and females 18 - 74 years of age inclusive
  • Fungal toenail infection of one or both of the large (great) toenails
  • The nail infection must be due to a dermatophyte, (mixed infections [dermatophyte and non-dermatophyte] are not allowed)
  • Willingness not to have professional pedicures or application of any nail polish product or nail cosmetics to the toenails after the screening visit

Exclusion Criteria

  • History of any significant chronic fungal disease other than onychomycosis or immunocompromised condition
  • Any abnormalities of the nail or previous surgery of the toenail that could prevent a normal appearing nail if clearing of infection is achieved
  • Significant confounding conditions as assessed by the study doctor
  • Participation in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study
  • No administration of systemic antifungal medications within 6 months prior to screening visit
  • No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
  • Tinea pedis (athlete's foot) that would require systemic treatment

Other protocol-defined inclusion/exclusion criteria may apply

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02798380). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search